Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson’s Disease Patients
暂无分享,去创建一个
Sylvie Retout | Sebastian Ueckert | Nicolas Frey | Simon Buatois | N. Frey | S. Ueckert | S. Retout | Simon Buatois
[1] J. Jankovic,et al. Functional decline in Parkinson disease. , 2001, Archives of neurology.
[2] K. Marder,et al. Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.
[3] N. Jetté,et al. The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[4] The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[5] Joel S. Perlmutter,et al. Assessment of Parkinson Disease Manifestations , 2009, Current protocols in neuroscience.
[6] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[7] Andrew C. Hooker,et al. Improved Utilization of ADAS-Cog Assessment Data Through Item Response Theory Based Pharmacometric Modeling , 2014, Pharmaceutical Research.
[8] W. Poewe,et al. Effects of rasagiline on the progression of nonmotor scores of the MDS‐UPDRS , 2015, Movement disorders : official journal of the Movement Disorder Society.
[9] F. Baker. The basics of item response theory , 1985 .
[10] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[11] J. Jankovic,et al. The heterogeneity of Parkinson's disease , 1985, Neurology.
[12] J. Nutt,et al. Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[13] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[14] J. Nutt,et al. Parkinson's disease , 2004, The Lancet.
[15] Ss Beal,et al. NONMEM User’s Guides. (1989–2009) , 2009 .
[16] M. Karlsson,et al. Modeling a Composite Score in Parkinson’s Disease Using Item Response Theory , 2017, The AAPS Journal.
[17] Mats O. Karlsson,et al. Comparison of proportional and differential odds models for mixed-effects analysis of categorical data , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[18] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[19] M. Frasier,et al. Parkinson's Disease Biomarkers: Resources for Discovery and Validation , 2014, Neuropsychopharmacology.
[20] J. Nutt,et al. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. , 2012, British journal of clinical pharmacology.
[21] A. Stiggelbout,et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[22] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[23] J. Nutt,et al. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.